Ru-106 plaque radiotherapy for vasoproliferative tumors of retina: a 15-year single-center experience

Navid Abolfathzadeh, Masood Naseripour, Ramin Jaberi, Zohreh Azma, Sayyed Amirpooya Alemzadeh, Mona Arbab, Ahad Sedaghat

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Purpose: This study evaluates the outcomes of ruthenium-106 (Ru-106) plaque brachytherapy for vasoproliferative tumors (VPTs) of the ocular fundus in a single referral ocular oncology center. Methods: The clinical charts of all patients diagnosed with VPT who underwent plaque radiotherapy from 2002 to 2017 were reviewed. Clinical features, types of treatment, outcomes and complications were evaluated. Results: Of 46 patients with VPT diagnosis in our ocular oncology clinic, 25 (54.34%) cases were treated with Ru-106 plaque brachytherapy. Eleven patients (44%) were male, and the mean age at the time of diagnosis was 40.92 ± 13.11 years. The mean follow-up time was 47.56 ± 36.87 months. Inferotemporal quadrant was the most common site of the tumor (64.00%). The mean delivered apex and scleral dose was 101.56 ± 6.51 and 412.26 ± 113.66 Gray (Gy), respectively. Initial tumor length, width and thickness were 10.26 ± 3.42, 8.05 ± 2.83 and 4.27 ± 1.10 mm, respectively. The mean tumor thickness decreased to 2.60 ± 0.63 mm, postoperatively. Complete resolution of subretinal fluid around the tumor was achieved in 81.80% of cases. Visual acuity was more than 20/400 in 64% of patients before treatment and 60% of patients at last follow-up. Conclusion: Our study showed that Ru-106 plaque radiotherapy is an effective and safe method of treatment in VPTs.

Original languageEnglish (US)
Pages (from-to)2095-2102
Number of pages8
JournalInternational Ophthalmology
Issue number8
StatePublished - Aug 1 2020
Externally publishedYes


  • Plaque radiotherapy
  • Primary
  • Retina
  • Ru-106
  • Secondary
  • Vasoproliferative tumor

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Ru-106 plaque radiotherapy for vasoproliferative tumors of retina: a 15-year single-center experience'. Together they form a unique fingerprint.

Cite this